Akèy › Myelofibroz › Ohio › Cincinnati

Etid klinik pou Myelofibroz nan Cincinnati, OH

5 etid pou Myelofibroz ap chèche patisipan nan sit nan ak bò kote Cincinnati (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Ap rekriteFaz 1

University of Cincinnati, Cincinnati

Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT06343805

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Ap rekriteFaz 1

Cincinnati Children's Hospital Medical Center, Cincinnati
University of Cincinnati, Cincinnati

Laj 13 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT04771572

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Ap rekriteEtid obsèvasyon

Massive Bio SYNERGY-AI site, Cincinnati

Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Ap rekriteFaz 3

University of Cincinnati Medical Center, Cincinnati

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2025 · NCT06479135

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Ap rekriteFaz 1/2

University of Cincinnati (UC), Cincinnati

Laj 18 ak plis · Tout sèks · Mizajou Feb 21, 2023 · NCT05280509

Etid Myelofibroz nan lòt vil

Lòt etid nan Cincinnati

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.